BYDUREON® exénatide

Bydureon® (suspension injectable d'exénatide à libération prolongée en stylo pré-rempli) est un agoniste du récepteur du glucagon-like peptide-1 (GLP-1), injectable une fois par semaine, présenté sous forme d'un stylo unidose, indiqué pour améliorer le contrôle glycémique chez les adultes atteints d'un diabète de type 2.

Références

  1. Henry RR, Klein EJ, Han J, Iqbal N. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. Diabetes Technol Ther. 2016;18(11):677-686.
  2. Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2(6):464-473.
  3. Bydureon stylo, résumé des caractéristiques du produit, version la plus récente
  4. Données consignées, AstraZeneca Pharmaceuticals LP, 3211825. 2016.
  5. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
  6. Wysham CH, MacConell LA, Maggs DG, Zhou M, Griffin PS, Trautmann ME. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. Mayo Clin Proc. 2015;90(3):356-365.
  7. Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33(6):1255-1261.
  8. Macconell L, Pencek R, Li Y, Maggs D, Porter L. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31-41.
  9. LaRue S, Malloy J. Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes. J Diabetes Sci Technol. 2015;9(4):815-821.
  10. Diamant M, Van GL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION 3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243.
  11. Hauber AB, Nguyen H, Posner J, Ervin C, LaRue S, Kalsekar I. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetes. Poster présenté lors de : International Society for Pharmacoeconomics and Outcomes Research of the 19th Annual International Meeting; 31 mai-4 juin 2014 ; Montréal, Québec, Canada. Présentation de poster. 2016.
  12. DeYoung MB, Macconell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145-1154.
  13. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrin Metab. 2011;96(5):1301-1310.
  14. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124.
  15. Trautman ME. Trautmann ME, Van Gaal L, Han J, Hardy E. Three-year efficacy and safety of exenatide once weekly: a pooled analysis of 3 trials. Poster présenté lors du : 51e congrès annuel de l'Association européenne pour l'étude du diabète ; 14 - 18 septembre 2015. Stockholm, Suède. Poster. 2016.
  16. Standards of Medical Care in Diabetes-2016. Diabetes Care. 2016;39(suppl 1):S1-S119. Diabetes Care. 2016.
  17. Résumé des caractéristiques du produit Lantus. 2015. 2016.
  18. Pistrosch et al. Pistrosch F, Köhler C, Schaper F, Landgraf W, Forst T, Hanefeld M. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol. 2013;50(4):587-595. 2017. 
  19. Données internes, AstraZeneca Pharmaceuticals LP, 3150204. 2016. 
  20. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism andregulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17(3):183-190. Diabetes Spectrum. 2016.
  21. Lim GE, Brubaker PL. Glucagon-like peptide 1 secretion by the L-cell: the view from within. Diabetes. 2006;55(suppl 2):S70-S77. Diabetes. 2016.
  22. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77-88.
  23. Astrazeneca Pharmaceuticals LP. Rapport d'évaluation périodique principale du rapport bénéfices-risques (20). 2016.Données internes, AstraZeneca Pharmaceuticals LP, 993604.011. 2016. 
  24. ClinicalTrials.gov. Clinical Trials gov. https://clinicaltrials.gov/ct2/results?term=exenatide&Search=Search.
  25. US National Library of Medicine. National Institutes of Health. www ncbi nlm nih gov. http://www.ncbi.nlm.nih.gov/pmc/?term=exenatide. Consulté le 25 septembre 2015.
  26. Wysham CH, et al. Poster 1041-P. Presented at the American Diabetes Association’s 76th Scientific Sessions (ADA 2016), New Orleans, LA, June 40-14, 2016
  27. Klein EJ. Klein EJ, Henry RR, Malloy J, et al. DURATION-1 extension: efficacy and tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes mellitus. Poster présenté lors du : 50e congrès annuel de l'Association européenne pour l'étude du diabète ; 15 - 19 août 2014 ; Vienne, Autriche. Poster. 2016.
  28. Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119-1133.
  29. Monnier L, Colette C, Owens D. Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther. 2011;13 Suppl 1:S25-S32.
  30. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-885.
  31. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-2514.
  32. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011;34(2):510-517.
  33. Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol. 2012;166(2):159-170.
  34. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION 2): a randomised trial. Lancet. 2010;376(9739):431-439.
  35. Diamant et al. Annexe complémentaire à : Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2(6):1-12. Supplementary appendix. 2016.
  36. 3024913. Données internes, AstraZeneca Pharmaceuticals LP, 3024913. 2016.
  37. Données consignées. AstraZeneca Pharmaceuticals LP, 3123823. 2016.

NS ID BE-1052-RD05/2017-WEB Local code 660